Gladman DD, Rigby WFC, Azevedo VF, et al. Efficacy and safety of tofacitinib, an oral janus kinase inhibitor, in patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors: OPAL BEYOND, a randomized, double-blind, placebo-controlled, phase 3 trial. EULAR 2017, OP0202.
Anti-IL17A verbetert de uitkomsten van PsA
mrt 2017 | Arthritis psoriatica